Bioxyne (ASX:BXN) said its unit Breathe Life Sciences UK has received funding of about AU$1.7 million from South of Scotland Enterprise to establish a medicinal cannabis manufacturing and distribution facility in the UK, according to a Monday filing with the Australian bourse.
Application for the required licences will be completed in 2026, the filing said.
Shares of the company fell 5% in recent Monday trade.